| D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C: Human dose prediction and first‐in‐human (FIH) trial design. | | | | Travel, Accommodations, Expenses - D3 Bio | | | | Travel, Accommodations, Expenses - D3 Bio | | | | Travel, Accommodations, Expenses - D3 Bio | | | No Relationships to Disclose | | | | Travel, Accommodations, Expenses - D3 Bio | | | | Travel, Accommodations, Expenses - D3 Bio | | | | Travel, Accommodations, Expenses - D3 Bio | | | | Travel, Accommodations, Expenses - D3 Bio | | | | Travel, Accommodations, Expenses - D3 Bio | | | | | Stock and Other Ownership Interests - D3 Bio | Travel, Accommodations, Expenses - D3 Bio |
| |